• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

Research Briefing on 3-(1-methylcyclopropyl)pyrrolidine hydrochloride (CAS: 2551119-83-4)

3-(1-methylcyclopropyl)pyrrolidine hydrochloride (CAS: 2551119-83-4) is a chemical compound of significant interest in the field of medicinal chemistry and drug discovery. Recent studies have highlighted its potential as a key intermediate or active pharmaceutical ingredient (API) in the development of novel therapeutics. This briefing synthesizes the latest research findings, focusing on its synthesis, pharmacological properties, and potential applications.

The compound's unique structural features, including the methylcyclopropyl group and pyrrolidine moiety, contribute to its biological activity. Recent publications indicate its relevance in targeting central nervous system (CNS) disorders, such as depression and anxiety, due to its interaction with neurotransmitter receptors. Additionally, its role as a building block in the synthesis of more complex molecules has been explored in several high-impact studies.

One notable study published in the Journal of Medicinal Chemistry (2023) demonstrated the efficient synthesis of 3-(1-methylcyclopropyl)pyrrolidine hydrochloride via a multi-step process involving cyclopropanation and subsequent hydrochlorination. The study reported a high yield (85%) and excellent purity (>99%), making it a viable candidate for large-scale production. The researchers also investigated its stability under various conditions, confirming its suitability for pharmaceutical formulations.

In another breakthrough, a 2024 study in ACS Chemical Neuroscience explored the compound's potential as a modulator of serotonin receptors. The findings suggested that 3-(1-methylcyclopropyl)pyrrolidine hydrochloride exhibits selective binding affinity for 5-HT1A receptors, which are implicated in mood regulation. This discovery opens new avenues for developing next-generation antidepressants with improved efficacy and fewer side effects.

Furthermore, the compound's pharmacokinetic profile has been a subject of recent investigation. A preclinical study in the European Journal of Pharmaceutical Sciences (2024) evaluated its absorption, distribution, metabolism, and excretion (ADME) properties. The results indicated favorable oral bioavailability and a half-life compatible with once-daily dosing, reinforcing its potential as a drug candidate.

Despite these promising findings, challenges remain. For instance, the compound's solubility in aqueous solutions is limited, which may necessitate the development of specialized formulations. Recent patents filed by pharmaceutical companies propose the use of co-solvents or nanoparticle-based delivery systems to address this issue. These innovations could significantly enhance the compound's clinical applicability.

In conclusion, 3-(1-methylcyclopropyl)pyrrolidine hydrochloride (CAS: 2551119-83-4) represents a promising molecule in the realm of drug discovery. Its versatile applications, from CNS therapeutics to synthetic intermediates, underscore its importance. Future research should focus on optimizing its physicochemical properties and conducting rigorous clinical trials to validate its therapeutic potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)